Physician profile
Joseph M Ferguson
NPI 1811986441
$2,253.35
in general payments reported to CMS, 2019-2025
29 companies · $226 in 2025
The $226 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $725 · 2021: $985 · 2022: $15.62 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $226.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $270.83 | 2019-2025 | Rybelsus, Ozempic |
| Esperion Therapeutics, INC. | $191.24 | 2020-2022 | |
| Lilly USA, LLC | $176.08 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $151.21 | 2020-2025 | Farxiga |
| Amarin Pharma, INC. | $137.84 | 2020-2021 | |
| Abbvie INC. | $133.02 | 2021 | |
| Allergan, INC. | $119.30 | 2020 | |
| Amgen INC. | $119.26 | 2019-2025 | Repatha, Otezla |
| Upsher-Smith Laboratories LLC | $93.35 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $90.47 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $85.22 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.43 | 2019-2021 | |
| Pfizer INC. | $69.98 | 2020-2025 | |
| Supernus Pharmaceuticals, INC. | $66.94 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $62.67 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $46.69 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.96 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $42.85 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.13 | 2020-2021 | |
| Astellas Pharma US INC | $41.46 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $35.62 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $32.37 | 2020 | |
| Horizon Therapeutics Plc | $29.36 | 2021 | |
| Exact Sciences Corporation | $21.69 | 2025 | The Cologuard Plus Collection Kit |
| Scilex Pharmaceuticals INC. | $17.16 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $15.19 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.57 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.33 | 2019 | |
| Glaxosmithkline, LLC. | $11.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Ferguson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.